Type1diabetes
Conditions
Brief summary
To assess the integration of the DreaMed Advisor Pro tool into a real-world clinical practice using both in person and virtual visits to assess benefits in glycemia, as measured by the glucose management indicator and other glucose metrics. To determine acceptability of the DreaMed Advisor Pro tool both from a person with diabetes as well as a health care provider perspective. To quantify the potential reimbursement potential that could be generated with use of the DreaMed Advisor Pro.
Interventions
DEVICEDreaMed Advisor Pro
Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
Sponsors
DreaMed
Yale University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
1. Participant with Type 1 diabetes 2. Age ≥ 6 years to \<30 years 3. Using Insulin infusion pump (CSII) therapy including those with low glucose suspend and predictive low glucose suspend features 1. Insulin pump must not use automated insulin delivery (closed loop, artificial pancreas) 2. Total daily dose of insulin must be greater than 0.5 units/kg/day 4. Participants / parents are required to have minimum computer skills and access to a computer in order to upload their personal devices (Pump, BG meter etc) to Tidepool. 5. Participants using Dexcom sensors will allow access to their account for the study duration 6. Participants not using CGM must agree to test BG at least 4 times a day at appropriate intervals 7. Participants / parents will have to have a smartphone (Apple or Android and Windows)
Exclusion criteria
1. An episode of diabetic ketoacidosis within the month prior to study entry 2. Any significant diseases / conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety, 3. Current participation in any other interventional study 4. Female subject who is pregnant or lactating or planning to become pregnant within the planned study duration 5. Severe hypoglycemia within six months prior to enrollment as defined by the ADA and Endocrine Society 6. Current use of the following medications: medications that are used to lower blood glucose such as Pramlintide, Metformin and GLP-1 analogs. Beta blockers, glucocorticoids and other medications, which in the judgment of the investigator would be a contraindication to participation in the study (Anticoagulant therapy e.g. Plavix, LMW heparin, Coumadin, Immunosuppressant therapy) 7. Participants suffers from an eating disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in glucose control with the use of DreaMed | 6 months | Glucose mangement indicator (GMI) will be used to determine glucose control. The GMI indicates the average A1C level that would be expected based on mean glucose measured in a large number of individuals with diabetes. Mean glucose ideally is derived from at least 14 days of CGM data |
Outcome results
None listed